Newsroom | 4781 results

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2025 third quarter ended June 30, 2025. The Company is hosting a conference call today, August 7, 2025, at 4:30 p.m. ET to discuss the results. “Arrowhead continues to achieve strong execution in discovery, clinical and regulatory, and business development. Our pipeline has become quite mature, with four Arrowhead discovered candidates currently in pivotal Phase 3 s...

CALGARY, Alberta--(BUSINESS WIRE)--Orpyx launches next-gen sensory insole program to prevent diabetic foot ulcers, reduce costs, and support value-based care through remote monitoring....

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM) has announced a voluntary medical device correction for select t:slim X2 insulin pumps to address a potential speaker-related issue that can trigger an error resulting in a discontinuation of insulin delivery. The error, which appears as a Malfunction 16 alarm to the user, will stop insulin delivery and terminate communication between the insulin pump and the continuous glucose monitoring (CGM) device. If not addressed, this...

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months ended June 30, 2025. Second Quarter Financial Highlights: Revenue of $649.1 million, up 32.9%, or 31.3% in constant currency, exceeds the high end of the Company’s guidance range of 26.0% in constant currency Total Omnipod revenue of $639.0 million, up 33.0%, o...

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended June 30, 2025 and provided full year 2025 guidance. Second Quarter 2025 Highlights Achieved record second quarter sales both in the United States (U.S.) and internationally. Demonstrated year-over-year and sequential gross margin improvement. Initiated an early access program for the t:slim X2™ insulin pump w...

LONDON & BOSTON--(BUSINESS WIRE)--Keyron appoints former FDA and Boston Scientific leaders as ForePass—a breakthrough device for severe metabolic disease—prepares for clinical trials...

PASADENA, Calif.--(BUSINESS WIRE)--New study shows the Vivio System enables early heart failure detection and triage of symptomatic patients in a primary care office visit....

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--AdaptHealth Corp. (NASDAQ: AHCO) (“AdaptHealth” or the “Company”), a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services, announced today financial results for the second quarter ended June 30, 2025. Second Quarter Results and Highlights All comparisons are to the quarter ended June 30, 2024 unless otherwise stated. Net revenue was $800.4 million compared to $806....

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--AdaptHealth Corp. (NASDAQ: AHCO) (“AdaptHealth” or the “Company”), a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services, announced today that they will participate in the Canaccord Genuity 45th Annual Growth Conference, being held in Boston, on Wednesday, August 13, 2025, including a fireside chat at 8:00am ET. The webcast link will be available on the Compan...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the second quarter ended June 30, 2025, and reiterated full year 2025 financial guidance. “Vertex delivered a strong quarter of revenue growth with each of our three product launches — ALYFTREK, JOURNAVX, and CASGEVY — contributing, as well as continued advancement of our clinical programs,” said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex....